THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 108 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $29,963 | -16.6% | 3,472 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $35,935 | -21.5% | 3,472 | -14.9% | 0.00% | 0.0% |
| Q4 2022 | $45,755 | +23.8% | 4,078 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $36,947 | -5.2% | 4,078 | 0.0% | 0.00% | +100.0% |
| Q1 2022 | $38,986 | -71.3% | 4,078 | -66.8% | 0.00% | -50.0% |
| Q4 2021 | $135,926 | +143.9% | 12,301 | +63.3% | 0.00% | +100.0% |
| Q3 2021 | $55,737 | -79.5% | 7,532 | -43.4% | 0.00% | -75.0% |
| Q1 2021 | $271,718 | +7.3% | 13,313 | -6.6% | 0.00% | 0.0% |
| Q4 2020 | $253,276 | -15.3% | 14,253 | 0.0% | 0.00% | -20.0% |
| Q2 2020 | $299,170 | +5.1% | 14,253 | -2.5% | 0.01% | 0.0% |
| Q3 2019 | $284,681 | +19.3% | 14,614 | 0.0% | 0.01% | +25.0% |
| Q2 2019 | $238,647 | -28.0% | 14,614 | 0.0% | 0.00% | -33.3% |
| Q1 2019 | $331,299 | -11.4% | 14,614 | 0.0% | 0.01% | -14.3% |
| Q4 2018 | $373,972 | -40.2% | 14,614 | -20.6% | 0.01% | +75.0% |
| Q2 2014 | $625,000 | – | 18,407 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Madison Avenue Partners, LP | 7,012,226 | $60,515,510 | 8.59% |
| Irenic Capital Management LP | 2,760,948 | $23,826,981 | 6.76% |
| Newtyn Management, LLC | 1,841,560 | $15,892,663 | 3.92% |
| Weiss Asset Management LP | 7,457,060 | $64,354,428 | 3.81% |
| Park West Asset Management LLC | 1,983,251 | $17,115,456 | 1.57% |
| Baupost Group | 7,419,226 | $64,028 | 1.23% |
| Oasis Management Co Ltd. | 953,254 | $8,226,582 | 0.36% |
| Chescapmanager LLC | 287,333 | $2,479,684 | 0.32% |
| GSA CAPITAL PARTNERS LLP | 325,985 | $2,813 | 0.24% |
| Virtus ETF Advisers LLC | 29,232 | $252,272 | 0.15% |